Lab tests confirmed metabolites, some of which activated CB1
In vitro human hepatocyte incubation of 5F-MDMB-PINACA, 5F-MDMB-PICA, 5F-EMDB-PICA, 4F-MDMB-BICA, and 4F-MDMB-BINACA and cannabinoid receptor 1 activity profiling of major human metabolites.
AI Summary
This study asked whether major metabolites of five fluorinated synthetic cannabinoid receptor agonists could be confirmed with reference standards and whether those metabolites activate CB1. Researchers incubated the compounds with human hepatocytes in vitro, identified metabolites using mass spectrometry, and tested parent compounds and metabolites in a recombinant-cell activity assay. This was a laboratory study, not a trial in people.
The researchers confirmed 16 of 20 assessed metabolites. Ten major, rapidly formed metabolites—including hydroxylated products, oxidative defluorination products, and ester-hydrolysis products—showed high to moderate CB1 potency, with reported EC₅₀ values from 96.3 nM to 8.07 μM. Metabolites that had undergone multiple transformations showed little or no receptor activation. These findings can help support synthetic-cannabinoid detection and clarify possible metabolite activity, but the in vitro results cannot establish effects or harms in people; this is an abstract-based summary.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
In septic rats, lenabasum reduced lung injury markers over 24 hours
Endocannabinoid levels differed in RA and tracked disease activity in women
Canine tumours show varied CB1 and CB2 expression; treatment effects remain…
Explore More Research
Stay informed about the latest cannabis science.